Impact BiomedicalIBO
13F holders, Q4 2024 (December 31)10holders +1
5new positions
4sold out
$1.44avg. 13F price*
At the end of Q4 2024, 10 institutions reported holding Impact Biomedical Inc. (IBO) in their 13F filings, up 1 from Q3 2024. 5 opened new positions and 4 sold out. The largest holders were Geode Capital Management, LLC ($30K), FNY Investment Advisers, LLC ($18K) and State Street Corp. ($16K).
- Company
- Impact Biomedical Inc.
- CUSIP
- 45259L205
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2024 → Q4 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 5 | $70K |
| Exits | 4 | $54K |
All 13F filers, Q3 2024 → Q4 2024: 52,640 shares bought and 29,620 shares sold, net +23,020 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 10 holders
| Geode Capital Management, LLC | 0.00% | New | 20,774 | $30K |
| FNY Investment Advisers, LLC | 0.01% | New | 12,600 | $18K |
| State Street Corp. | 0.00% | New | 11,171 | $16K |
| UBS Group AG | 0.00% | Add +141633.3% | 4,252 | $6K |
| Tower Research Capital LLC (TRC) | 0.00% | New | 3,760 | $5K |
| NFSG Corp | 0.00% | New | 86 | $125 |
| Wells Fargo & Company | 0.00% | No change | 29 | $42 |
| Bank of America Corp. | 0.00% | Reduce -99.3% | 17 | $24 |
| Danske Bank A/S | 0.00% | No change | 3 | $4 |
| Group One Trading LLC | 0.00% | No change | 1 | $1 |
"% of holder's portfolio" is IBO's weight in each manager's 13F, not the share of Impact Biomedical Inc. the manager owns.